Representatives from government, industry, research and patient groups met in Washington, D.C., Sept. 27-28 to discuss antisense-based therapies for neuromuscular disease
posted on October 1, 2010 - 2:24pm
This story was updated Oct. 6, 2010.
Researchers, clinicians, pharmaceutical industry executives, and representatives from advocacy groups, including MDA, met in Washington Sept. 27-28, 2010, to discuss moving forward with antisense-based therapies for neuromuscular disease.
MDA has awarded 38 grants totaling more than $12 million to support research into general muscle health and more than 15 neuromuscular diseases in its program
posted on February 1, 2012 - 10:00am
The Muscular Dystrophy Association has awarded 38 new grants totaling more than $12 million to fund research projects focused on its continuing mission to uncover the causes of, and develop therapies for, the more than 40 neuromuscular diseases in its program.
MDA's Board of Directors reviewed and approved the new grants based on recommendations from the Association's Scientific and Medical...
MDA has awarded $300,000 to Children's National Medical Center to maintain a valuable research mouse testing facility
posted on March 7, 2012 - 6:00am
The Muscular Dystrophy Association has given a $300,000 grant to the Center for Genetic Medicine Research (CGMR) at Children’s National Medical Center in Washington, D.C., to continue standardized and reliable preclinical studies of neuromuscular diseases.
Top researchers are discussing notable developments in neuroscience, including research in many neuromuscular diseases, at the annual American Academy of Neurology meeting April 21-28
posted on April 24, 2012 - 4:00am
Top scientists and clinicians from around the world are discussing the latest research in neuroscience, and the care of individuals with nerve and muscle diseases, at the 2012 annual meeting of the American Academy of Neurology in New Orleans, April 21-28.
Thirty-eight new grants support research in ALS, central core disease, spinal muscular atrophy, muscular dystrophy, and other diseases in MDA's program
posted on August 17, 2010 - 6:39pm
MDA has awarded 38 new research grants totaling more than $14 million and covering more than a dozen neuromuscular diseases.
MDA's Board of Directors met in Los Angeles July 16, where it reviewed and approved the new grants based on recommendations from the MDA Scientific and Medical Advisory Committees. Grants were scored and recommended for approval based on the capabilities of the...
Pediatric cardiologists and other experts at an MDA-sponsored meeting exchanged information and planned studies regarding the heart in DMD and BMD
posted on January 28, 2011 - 2:10pm
Although it’s clear that people with Duchenne and Becker muscular dystrophies should be closely monitored and treated by heart specialists, doctors and researchers at a recent MDA-sponsored meeting say there still are many unanswered questions about optimal clinical care of the DMD/BMD-affected heart.
MDA has awarded 44 new grants aimed at uncovering the underlying molecular causes of, and developing therapies for, many of the diseases in its program
posted on February 4, 2011 - 1:22pm
The Muscular Dystrophy Association has awarded 44 grants totaling $13.5 million to support research efforts aimed at advancing understanding of disease processes and uncovering new strategies for treatments and cures of muscular dystrophy and the more than 40 other diseases in the Association’s program.
The new grants were reviewed by MDA’s Scientific and Medical Advisory Committees, and approved...
'Muscle Gene Therapy' brings together the latest research in this promising field
posted on March 8, 2010 - 11:19am
MDA grantee Dongsheng Duan has published a book on the latest advances in gene therapy for muscle disease, particularly muscular dystrophies.
Duan, a professor of microbiology and immunology at the University of Missouri, served as editor of the book Muscle Gene Therapy and co-authored two of its 15 chapters. Duan is currently researching gene transfer therapy in dogs.
About the new book
